Blood pressure variability and microvascular dysfunction:the Maastricht Study by Zhou, Tan Lai et al.
 
 
 
Blood pressure variability and microvascular
dysfunction
Citation for published version (APA):
Zhou, T. L., Rensma, S. P., van der Heide, F. C. T., Henry, R. M. A., Kroon, A. A., Houben, A. J. H. M.,
Jansen, J. F. A., Backes, W. H., Berendschot, T. T. J. M., Schouten, J. S. A. G., van Dongen, M. C. J. M.,
Eussen, S. J. P. M., Dagnelie, P. C., Webers, C. A. B., Schram, M. T., Schalkwijk, C. G., van Sloten, T. T.,
& Stehouwer, C. D. A. (2020). Blood pressure variability and microvascular dysfunction: the Maastricht
Study. Journal of Hypertension, 38(8), 1541-1550. https://doi.org/10.1097/HJH.0000000000002444
Document status and date:
Published: 01/08/2020
DOI:
10.1097/HJH.0000000000002444
Document Version:
Publisher's PDF, also known as Version of record
Document license:
Taverne
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page
numbers.
Link to publication
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 06 Jan. 2021
D
ow
nloaded
from
http://journals.lw
w
.com
/jhypertension
by
BhD
M
f5ePH
Kav1zEoum
1tQ
fN
4a+kJLhEZgbsIH
o4XM
i0hC
yw
C
X1AW
nYQ
p/IlQ
rH
D
3i3D
0O
dR
yi7TvSFl4C
f3VC
1y0abggQ
ZXdtw
nfKZBYtw
s=
on
11/03/2020
Downloadedfromhttp://journals.lww.com/jhypertensionbyBhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC1y0abggQZXdtwnfKZBYtws=on11/03/2020
 Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Blood pressure variability andmicrovascular
dysfunction: theMaastricht Study
Tan Lai Zhoua,b,, Sytze P. Rensmaa,b,, Frank C.T. van der Heidea,b,, Ronald M.A. Henrya,b,c,
Abraham A. Kroona,b, Alfons J.H.M. Houbena,b, Jacobus F.A. Jansend,e, Walter H. Backesd,e,
Tos T.J.M. Berendschotf, Jan S.A.G. Schoutenf,g, Martien C.J.M. van Dongenh,i,
Simone J.P.M. Eussenb,i, Pieter C. Dagneliea,b, Carroll A.B. Webersf, Miranda T. Schrama,b,c,
Casper G. Schalkwijka,b, Thomas T. van Slotena,b,j,k, and Coen D.A. Stehouwera,b
Background: Microvascular dysfunction (MVD) contributes
to stroke, dementia, depression, retinopathy and chronic
kidney disease. However, the determinants of MVD are
incompletely understood. Greater blood pressure variability
(BPV) may be one such determinant.
Methods and results: We used cross-sectional data of
The Maastricht Study (n¼2773, age 59.9 years; 51.9%
men) to investigate whether greater very short- to mid-
term BPV is associated with various MVD measures. We
standardized and averaged within-visit, 24-h and 7-day
BPV into a systolic and a diastolic BPV composite score.
MVD measures included a composite score of MRI cerebral
small vessel disease (CSVD) features (total brain
parenchymal volume, white matter hyperintensity volume,
lacunar infarcts and cerebral microbleeds), a composite
score of flicker light-induced retinal arteriolar and venular
dilation response, albuminuria, heat-induced skin
hyperemia and a composite score of plasma biomarkers of
MVD (sICAM-1, sVCAM-1, sE-selectin and von Willebrand
Factor). We used linear regression adjusted for age, sex,
glucose metabolism status, mean 24-h systolic or DBP,
cardiovascular risk factors and antihypertensive medication.
We found that higher systolic and diastolic BPV composite
scores (per SD) were associated with higher albuminuria
[higher ratio, 1.04 (95% CI 1.00–1.08) and 1.07 (1.03–
1.11), respectively], but not with other measures of MVD
tested.
Conclusion: Greater systolic and diastolic BPV was
associated with higher albuminuria, but not with CSVD
features, flicker light-induced retinal arteriolar and venular
dilation response, heat-induced skin hyperemia and plasma
biomarkers of MVD. This suggests that the
microvasculature of the kidneys is most vulnerable to the
detrimental effects of greater BPV.
Keywords: albuminuria, blood pressure, cardiovascular
disease, cerebral small vessel diseases, cohort study,
endothelium, epidemiology, imaging, magnetic resonance,
nitric oxide, type 2 diabetes mellitus
Abbreviations: BPV, blood pressure variability; CSVD,
cerebral small vessel disease; MVD, microvascular
dysfunction; sE-selectin, soluble E-selectin; sICAM-1,
soluble intercellular adhesion molecule-1; sVCAM-1,
soluble vascular adhesion molecule-1; UAE, urinary
albumin excretion; vWF, von Willebrand factor
INTRODUCTION
M
icrovascular dysfunction (MVD) is an important
contributor to various diseases that are (in part) of
microvascular origin, including stroke [1], demen-
tia [1], depression [1], retinopathy [2], and chronic kidney
disease [3]. However, the determinants of MVD are incom-
pletely understood. Greater blood pressure variability
(BPV), that is, greater fluctuations of blood pressure over
time, may be one such determinant.
Greater BPV may lead to MVD both via increases in
pulsatile pressure that can penetrate distally and damage
the microcirculation [4], and sudden falls in blood pressure
leading to reduced microvascular perfusion [5]. The micro-
vascular beds of organs with low vascular impedance (i.e.
the microvasculature of the brain, eyes and kidneys) may be
particularly vulnerable for these fluctuations in blood pres-
sure [4].
Microvascular function can be measured noninvasively
in various organs. These measures include MRI features of
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cerebral small vessel disease (CSVD, that is, lower total
brain parenchyma volume, higher white matter hyperin-
tensity volume, and presence of lacunar infarcts and cere-
bral microbleeds) [6]; flicker light-induced retinal arteriolar
and venular dilation response [7]; albuminuria (’urinary
albumin excretion’, UAE) [8]; heat-induced skin hyperemia
[7]; and plasma biomarkers of MVD [i.e. soluble intercellular
adhesion molecule-1 (sICAM-1), soluble vascular adhesion
molecule-1 (sVCAM-1), soluble E-selectin (sE-selectin) and
von Willebrand factor (vWF)] [9].
The associations between BPV and most of these various
MVD measures remain, however, incompletely under-
stood. To date, only five studies have evaluated the associ-
ation between BPV and CSVD features. These studies found
an association between greater very short-term to short-
term systolic and diastolic BPV and cerebral atrophy [10,11],
higher white matter hyperintensity volume [10–13], lacunar
infarcts [10,12], and enlarged perivascular spaces [10,14].
However, these studies were relatively small (n 155)
[11,13], done in selected populations (i.e. individuals with
hypertension [12], aged 70 years and older [15], or admitted
to the hospital [10,14]) or did not adjust for potentially
important confounders (i.e. mean blood pressure [11,13]
or lifestyle factors [12]). For UAE, most previous studies [16–
27], but not all [28–30], found an association with greater
very short-to mid-term systolic or diastolic BPV. However,
these studies did not adjust for potentially important con-
founders, including dietary habits and physical activity. For
plasma biomarkers of MVD, only one study has been done,
which included 190 individuals with newly diagnosed
hypertension. This study found an association between
greater short-term systolic BPV and higher sE-selectin
[31]. Currently, no studies have investigated the association
between BPV and flicker light-induced retinal arteriolar and
venular dilation or heat-induced skin hyperemia.
In view of the above, we investigated, in a large popu-
lation-based cohort, whether very short-term to mid-term
BPV (i.e. within-visit, 24-h and 7-day BPV) is associated
with a comprehensive set of MVD measures, including
CSVD features, flicker light-induced retinal arteriolar and
venular dilation response, UAE, heat-induced skin hyper-
emia and plasma biomarkers of MVD. We hypothesized
that greater BPV would be more strongly associated with
MVD in organs with a low vascular impedance, that is,
brain, eyes and kidneys, and would not be associated with
MVD in organs with a high vascular impedance, for
example, skin.
MATERIAL ANDMETHODS
Study population and design
We used data from The Maastricht Study, an observational
population-based cohort study. The rationale and method-
ology have been described previously [32]. In brief, the
study focuses on the cause, pathophysiology, complica-
tions and comorbidities of diabetes mellitus type 2 (T2D)
and is characterized by an extensive phenotyping
approach. Eligible for participation were all individuals
aged between 40 and 75 years and living in the southern
part of the Netherlands. Participants were recruited through
mass media campaigns, the municipal registries and the
regional Diabetes Patient Registry via mailings. Recruitment
was stratified according to known T2D status, with an
oversampling of individuals with T2D for reasons of effi-
ciency. The present report includes cross-sectional data
from 3451 participants who completed the baseline survey
between November 2010 and September 2013. The exami-
nations of each participant were performed within a time
window of 3 months. The study has been approved by the
institutional medical ethical committee (NL31329.068.10)
and the Minister of Health, Welfare, and Sports of the
Netherlands (Permit 131088-105234-PG). All participants
gave written informed consent. Data are available from
The Maastricht Study for any researcher who meets the
criteria for access to confidential data, and the correspond-
ing author may be contacted to request data.
Blood pressure measurements and
determination of blood pressure variability
A detailed description of the office, 24-h ambulatory and 7-
day home blood pressure measurements and determination
of BPV has been reported previously [33]. Briefly, within-
visit BPV was calculated as the standard deviation (SD) of
three consecutive office blood pressure measurements
assessed in the sitting position, with a 1-min interval, after
10min of rest [34]. The 24-h BPV was calculated as the
average real variability of blood pressure readings taken
every 15 min between 0800 and 2300 h, and every 30 min
between 2300 and 0800 h [34]. Seven-day BPV was calcu-
lated as the SD of home blood pressure measurements
taken twice, with a 1-min interval, each morning and
evening, for 7 consecutive days [34].
Microvascular dysfunction measures
For all MVD measures, participants were asked to refrain
from smoking and drinking caffeine-containing beverages
3 h before the measurement [35]. A light meal was allowed
until at least 90min prior to the examination. For retinal
measurements, pupils were dilated with 0.5% tropicamide
and 2.5% phenylephrine at least 15min before the start of
the examination. Skin blood flow measurements were
performed in a climate-controlled room at 24 8C [36]. Here,
we briefly describe the MVD measures used; a detailed
description, including the reproducibility of the MVD mea-
sures, is provided in the Extended Methods (Supplementary
Material, http://links.lww.com/HJH/B333).
Features of cerebral small vessel disease
Brain MRI measurements were implemented from Decem-
ber 2013 onwards and were available in 2313 of the 3451
participants (67%). Brain MRI was performed on a 3T MRI
scanner (Siemens Magnetom Prisma-fit Syngo MR D13D,
Erlangen, Germany). We evaluated four MRI CSVD fea-
tures, that is. total brain parenchyma volume, white matter
hyperintensity volume, lacunar infarcts and cerebral micro-
bleeds. Briefly, the MRI protocol consisted of a 3D T1-
weighted sequence, T2-weighted fluid-attenuated inver-
sion recovery (FLAIR), and a gradient recalled echo
(GRE) pulse sequence with susceptibility-weighted imag-
ing (SWI) [37]. T1-weighted images and FLAIR images were
analyzed by use of an automated method [38,39]. T1-
Zhou et al.
1542 www.jhypertension.com Volume 38  Number 8  August 2020
 Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
weighted images were segmented into grey matter, white
matter and cerebrospinal fluid volumes [38]. Intracranial
volume was calculated as the sum of grey matter, white
matter (including white matter hyperintensity volume) and
cerebrospinal fluid volumes. Total brain parenchyma vol-
ume was calculated as the sum of grey and white matter
volumes. T1-weighted and FLAIR images were used to
identify white matter hyperintensities [39]. White matter
hyperintensity volume was summed to assess total white
matter hyperintensity burden, and expressed relative to
intracranial volume. Lacunar infarcts were defined as focal
brain parenchyma defects of at least 3mm and less than
15mm in size with a similar signal intensity as cerebrospinal
fluid on all sequences and a hyperintense rim on FLAIR
images [6]. Cerebral microbleeds were rated on three-
dimensional T2 GRE imaging with SWI by use of the
Microbleed Anatomical Rating Scale [40], and were defined
as focal lesions of at least 2 mm and 10mm or less in size
with a hypointense signal [6]. The presence of lacunar
infarcts and cerebral microbleeds was rated manually by
three neuroradiologists.
Flicker light-induced retinal arteriolar and venular
dilation response
We measured retinal arteriolar and venular dilation to
flicker light exposure by the Dynamic Vessel Analyzer
(Imedos, Jena, Germany), as previously described [7,41].
Briefly, a baseline recording of 50 s was followed by 40-s
flicker light exposure followed by a 60-s recovery period.
We calculated baseline diameters (in measurement units) as
the average diameter during the 20–50 s recording. For
both the arteriolar and venular dilation, percentage dilation
over baseline was calculated using the average dilation
achieved at time points 10 and 40 s during the flicker
stimulation period.
Urinary albumin excretion
To assess UAE, participants were requested to collect two
24-h urine samples. Urinary albumin concentration was
measured with a standard immunoturbidimetric assay by
an automatic analyzer (because of a change of supplier, by
the Beckman Synchron LX20 and the Roche Cobas 6000)
and multiplied by collection volume to obtain 24-h UAE. A
urinary albumin concentration below the detection limit of
the assay was set at 1.5 mg/l (2mg/l for the Beckman
Synchron LX20 and 3mg/l for the Roche Cobas 6000)
before multiplying by collection volume. Only urine col-
lections with a collection time between 20 and 28h were
considered valid. If needed, UAE was extrapolated to 24-h
excretion. For this study, UAE was preferably based on the
average of two (available in 91.3% of participants) 24-h
urine collections.
Heat-induced skin hyperemia
We measured heat-induced skin hyperemia by laser Dopp-
ler flowmetry (Perimed, Järfälla, Sweden), as previously
described [7]. Briefly, skin blood flow at the wrist, expressed
in arbitrary perfusion units, was recorded unheated for
2min to serve as a baseline. After 2min, the temperature
of the laser Doppler probe was rapidly and locally
increased to 44 8C and was kept constant until the end of
the registration. Skin hyperemia was expressed as the
percentage increase in average perfusion unit during the
23min heating phase over the 2min average baseline
perfusion unit.
Plasma biomarkers of microvascular dysfunction
We measured four plasma biomarkers of MVD: sICAM-1,
sVCAM-1, sE-selectin and vWF [42]. sICAM-1, sVCAM-1 and
sE-selectin were measured in EDTA plasma samples with
commercially available 4-plex sandwich immunoassay kits
with different standards and antibodies (Meso Scale Dis-
covery, Rockville, Maryland, USA).
Covariates
We determined glucose metabolism status according to the
WHO 2006 criteria as normal glucose metabolism, prediabe-
tes or T2D [43]. Education level was classified into three
groups: low (none, primary or lower vocational education
only), intermediate (intermediate general secondary, inter-
mediate vocational or higher general secondary education)
and high (higher vocational education or university level of
education). We determined alcohol consumption [none, low
(women 7, men 14units/week), high (women >7, men
>14units/week)], smoking status (never, former, current),
medication use, BMI, total/high density lipoprotein (HDL)
cholesterol ratio and prior cardiovascular disease as
described previously [7,8,32]. We defined hypertension as
use of antihypertensive medication, and/or systolic office
blood pressure At least 140mmHg and/or diastolic office
blood pressure at least 90mmHg [44]. Estimated glomerular
filtration rate (eGFR) was computed with the CKD-EPI
(Chronic Kidney Disease Epidemiology collaboration) for-
mula using serum creatinine and cystatin C [45]. Plasma
biomarkers of low-grade inflammation (i.e. high-sensitive
C-reactive protein, serum amyloid A, interleukin-6, interleu-
kin-8 and tumor necrosis factor alpha) were determined as
described previously [32,46]. Carotid–femoral pulse wave
velocity, a measure of aortic stiffness [44], was measured
according to international guidelines [47] with the use of
applanation tonometry (Sphygmocor; Atcor Medical, Syd-
ney,Australia) at the right commoncarotid and right common
femoral arteries. As described previously, we used question-
naires to assess theMediterraneandiet score (’diet score’) [48],
moderate-to-vigorous physical activity [32] and socioeco-
nomic status (income level and occupation status) [49].
Statistical analysis
We inversed (multiplying by 1) total brain parenchyma
volume, flicker light-induced retinal arteriolar and venular
dilation response and heat-induced skin hyperemia so that
higher values indicated worse microvascular function. White
matter hyperintensity volume and UAE were log-transformed
(base 2) to normalize their skewed distribution.
We summarized the three BPV measures (i.e. within-
visit, 24-h and 7-day BPV) into a systolic and diastolic BPV
composite score, as done previously [50]. We hypothesized
that each BPV measure is associated with MVD according to
similar underlying mechanisms, that is, each greater BPV
measure may be related to an increased pulsatile load, and
BPV and microvascular dysfunction
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these increased pulsatile loads may damage the microvas-
cular beds of various organs in a similar way. Furthermore,
a composite score reduces the influence of noise, or mea-
surement error, of its components [51], and it reduces the
chance of a type 1 error. The BPV composite scores were
calculated when at least data on two of the three BPV
measures were available. The scores were calculated by
summation and subsequent standardization of the z-scores
of the three systolic and diastolic BPV measures, respec-
tively, so that a 1-unit increment is expressed as a 1-SD
increment in the BPV composite score.
We also calculated separate composite scores for the
CSVD features, for the flicker light-induced retinal arteriolar
and venular dilation response and for the plasma biomark-
ers of MVD, respectively. The CSVD composite score was
calculated as described previously [52]; one point per CSVD
feature was assigned based on the following cut-offs: for
lower total brain parenchyma volume quartile 1 vs. quar-
tiles 2–4; for higher white matter hyperintensity volume
quartile 4 vs. quartiles 1–3; and for lacunar infarcts and
cerebral microbleeds presence vs. absence. The points for
each feature were combined to compute the CSVD com-
posite score (range 0–4). The composite scores for retinal
arteriolar and venular dilation and plasma biomarkers of
MVD were calculated by summation and averaging of the z-
scores of the flicker light-induced retinal arteriolar and
venular dilation responses and the four plasma biomarkers
of MVD, respectively.
We used Poisson regression to investigate the associa-
tion between the systolic and diastolic BPV composite
scores and the CSVD composite score. We used linear
regression to investigate the association between the sys-
tolic and diastolic BPV composite scores and the retinal
arteriolar and venular dilation composite score, UAE, skin
hyperemia and the plasma biomarkers of MVD composite
score. All analyses were adjusted for age and sex (model 1),
and additionally for glucose metabolism status (model 2),
mean 24-h SBP or DBP (wherever appropriate) (model 3),
and education level, BMI, smoking status, alcohol con-
sumption, total/HDL cholesterol ratio, lipid-modifying
medication and the individual classes of antihypertensive
medication (i.e. beta blockers, diuretics, calcium channel
blockers, angiotensin-converting enzyme inhibitors and
angiotensin II receptor blockers) (model 4). For analyses
with the CSVD composite score, results were exponentiated
to represent the risk ratio per point higher score. For
analyses with log-transformed UAE as the outcome, regres-
sion coefficients were back-transformed and expressed as
higher ratio per SD higher systolic and diastolic BPV.
We tested interaction terms of the BPV composite scores
with age [53], sex [54], glucose metabolism status [55] and
hypertension status [12] to evaluate whether the associa-
tions between the BPV composite scores and the MVD
measures differed according to these factors.
Several sensitivity and additional analyses were per-
formed. First, we repeated the analysis with the individual
BPV measures as the determinant, that is, within-visit, 24-h
and 7-day systolic and diastolic BPV. Second, we repeated
the analysis using as the outcome the individual CSVD
features, the individual retinal arteriolar and venular dila-
tion response and the individual plasma biomarkers of
MVD, respectively. Third, we repeated the analysis with
additional adjustment for eGFR, prior cardiovascular dis-
ease, plasma biomarkers of low-grade inflammation and
carotid–femoral pulse wave velocity. These covariates were
entered into a separate model because of the risk of
overadjustment bias: these factors may be confounders,
but may also mediate any association between BPV and
MVD. Fourth, we repeated the analysis additionally adjust-
ing for the diet score, and moderate-to-vigorous physical
activity and for income level and occupation status (instead
of education level). Adjustment for these potential con-
founders was not included in the main analysis, as data
were missing in a relatively large number of participants
(n¼ 1133 missed data on one or more of these variables).
Fifth, we used microalbuminuria defined as at least 30mg/
24 h vs. less than 30mg/24 h as the outcome instead of UAE
per mg/24 h [56]. Sixth, we studied the association between
BPV and eGFR [continuously and categorically (60 vs.
<60ml/min/1.73 m2)].
All statistical analyses were performed with Statistical
Package for Social Sciences (v22.0; IBM, Chicago, Illinois,
USA). A P value of less than 0.05 was considered statistically
significant [57].
RESULTS
Study population
Figure 1 shows the derivation of the study population. In
total, 2773 participants had data available on the BPV
composite scores, all potential confounders and at least
one MVD measure, and were included in the analysis.
CSVD features were available in 1837 participants, retinal
arteriolar and venular dilation response in 1844, UAE in
2748, skin hyperemia in 1320 and plasma biomarkers of
MVD in 2726. These subpopulations were comparable with
regard to age, sex and cardiovascular risk profile (Supple-
mental Table S1, http://links.lww.com/HJH/B333). Partic-
ipants excluded because of missing data had greater BPV
and higher BMI and more often had prior cardiovascular
disease compared with those without missing data (Sup-
plemental Table S1, http://links.lww.com/HJH/B333).
Table 1 and Supplemental Table S2, http://link-
s.lww.com/HJH/B333 show the general characteristics for
the total study population and according to tertiles of the
systolic BPV composite score. Supplemental Table S3,
http://links.lww.com/HJH/B333 shows the characteristics
according to tertiles of the diastolic BPV composite score.
The mean age was 59.9 years, 51.9% were men and 26.9%
had T2D. In general, participants with the highest com-
pared with the lowest tertile of the systolic BPV composite
score were older, less often men, had a worse cardiovas-
cular risk profile and more often used lipid-modifying and
antihypertensive medication.
Blood pressure variability and microvascular
dysfunction
Higher systolic and diastolic BPV composite scores were
associated with higher UAE [1.04 (95% CI 1.00–1.08) and
1.07 (1.03–1.11) higher ratio per 1 SD higher systolic and
diastolic BPV composite score, respectively], after adjust-
ment for all potential confounders (Table 2, model 4).
Zhou et al.
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Systolic and diastolic BPV composite scores were not
associated with the other MVD measures: the CSVD com-
posite score, the retinal arteriolar and venular dilation
response composite score, skin hyperemia, and the plasma
biomarkers of MVD composite score, after full adjustment
(Table 2, model 4).
We did not observe consistent interactions with age, sex,
glucose metabolism status or hypertension status for the
associations between systolic and diastolic BPV and any of
the MVD measures (Supplemental Table S4, http://link-
s.lww.com/HJH/B333).
Sensitivity and additional analyses
For individual systolic and diastolic BPV measures, we
found the following results after full adjustment: systolic
and diastolic within-visit BPV were both not associated with
any measure of MVD; 24-h systolic BPV was not associated
with any measure of MVD; diastolic 24-h, BPV was associ-
ated with a higher CSVD composite score, retinal arteriolar
and venular dilation response composite score and UAE but
not with any other measure of MVD; 7-day systolic BPV was
associated with a higher CSVD composite score and plasma
biomarkers of MVD composite score, but not with any other
measure of MVD; and 7-day diastolic BPV was associated
with higher UAE and a higher plasma biomarker of MVD
composite score, but not with any other measure of MVD
(Supplemental Table S5, http://links.lww.com/HJH/B333).
When we repeated the analysis using each individual MVD
measure as the outcome, the systolic and diastolic BPV
composite scores were associated with higher levels of
sVCAM-1 and the systolic BPV composite score with higher
levels of vWF (Supplemental Table S6, http://link-
s.lww.com/HJH/B333). Results were similar when we addi-
tionally adjusted for eGFR, prior cardiovascular disease,
plasma biomarkers of low-grade inflammation, carotid–
femoral pulse wave velocity, diet score, moderate-to-vigor-
ous physical activity, or income level and occupation status
(Supplemental Tables S7–S14, http://links.lww.com/HJH/
B333). Each SD higher BPV composite score was associated
with higher odds of UAE at least 30 mg/24 h; odds ratios
were 1.19 (95% CI 1.02–1.38) for systolic BPV and 1.19 (95%
CI 1.02–1.37) for diastolic BPV (Fig. 2 and Supplemental
Table S15, http://links.lww.com/HJH/B333). The systolic
and diastolic BPV composite scores were not associated
with eGFR (Supplemental Table S16, http://links.lww.com/
HJH/B333).
DISCUSSION
We found that greater very short-term to mid-term systolic
and diastolic BPV are associated with higher UAE, but not
with other measures of MVD tested, that is, the CSVD
composite score, flicker light-induced retinal arteriolar
and venular dilation response composite score, heat-
induced skin hyperemia and the plasma biomarkers of
MVD composite score. The association with higher UAE
was independent of age, sex, mean 24-h systolic or diastolic
blood pressure, education level, and lifestyle and cardio-
vascular risk factors. The strength of this association cor-
responds to a 1.2 higher odds of UAE at least 30 mg/24 h as
compared with a UAE of less than 30mg/24 h per SD higher
systolic or diastolic BPV composite score.
The Maastricht Study
population
N = 3451
n = 3410
Excluded due to a diabetes type other than
type 2: n = 41
At least 2 BPV-indices
n = 3234
Missing data on:
•
•
•
•
•
•
•
•
•
•
Within-visit and 24-h BPV (n = 1)
Within-visit and 7-day BPV (n = 2)
24-hour and 7-day BPV (n = 173)
Complete data on potential
confounders
n = 2773
Missing data on potential confounders:*
Education level (n = 72)
Body mass index (n = 3)
Smoking status (n = 59)
Alcohol use (n = 65)
Lipid profile (n = 4)
Medication use (n = 4)
Mean 24-h blood pressure (n = 374)
Complete data on cerebral
small vessel disease
features
n = 1837
Complete data on heat-
induced skin hyperaemia
n = 1320
Complete data on urinary
albumin excretion
n = 2748
Complete data on plasma
biomarkers of
microvascular dysfunction
n = 2726
Complete data on flicker
light-induced retinal
arteriolar and venular
dilation response
n = 1844
FIGURE 1 Flowchart delineating the derivation of the study population. Not mutually exclusive. BPV, blood pressure variability.
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Our study findings are in agreement with most [16–27],
but not all [28–30], previous studies that investigated the
association between BPV and UAE. Our study adds to the
existing literature on UAE, as we were able to study this
association in the context of various other MVD measures,
and adjusted for potentially important confounders,
including dietary habits and physical activity. Previous
studies on BPV and UAE did not adjust for these potential
confounders.
In disagreement with our hypothesis, we did not find an
association between greater BPV and MVD measured in
organs with low microvascular impedance other than the
kidneys, that is, the brain and eyes, and with plasma
biomarkers of MVD, which at least partly reflect MVD in
organs with low microvascular impedance. A possible
explanation is that the kidney microvasculature has a lower
impedance than the brain and eye microvasculature, for
example, blood flow to the kidneys relative to organ weight
(360ml/min per 100 g kidney tissue) is higher than to the
brain (50 ml/min per 100 g brain tissue) [58]. The kidney
microvasculature may, therefore, in comparison be most
vulnerable to the detrimental effects of BPV.
Although we found no significant associations between
greater BPV and CSVD features, flicker light-induced retinal
arteriolar and venular dilation response and plasma bio-
markers of MVD, these measures nevertheless reflect MVD
in organs with low vascular impedance, and may thus be
vulnerable to an increased pulsatile load [59], albeit to a
lesser extent than UAE. Indeed, we found positive associ-
ations that were quantitatively similar for CSVD features,
TABLE 1. General study population characteristics
Tertiles of systolic BPV composite score
Characteristic
Total study population
(n¼2773)
Lowest tertile
(n¼921)
Middle tertile
(n¼934)
Highest tertile
(n¼918)
Demographics
Age (years) 59.98.2 57.88.6 60.37.8 61.77.6
Men 1,40 (51.9) 490 (53.2) 486 (52.0) 464 (50.5)
Lifestyle factors
Smoking status
Never 980 (35.3) 366 (39.7) 297 (31.8) 317 (34.5)
Former 1441 (52.0) 453 (49.2) 506 (54.2) 482 (52.5)
Current 352 (12.7) 102 (11.1) 131 (14.0) 119 (13.0)
Alcohol consumption
None 509 (18.4) 148 (16.1) 179 (19.2) 182 (19.8)
Low (women 7, men 14 units/week) 1550 (55.9) 562 (61.0) 516 (55.2) 472 (51.4)
High (women >7, men >14 units/week) 714 (25.7) 211 (22.9) 239 (25.6) 264 (28.8)
BMI (kg/m2 27.04.4 26.34.3 27.04.3 27.64.5
Cardiovascular risk factors
Total/HDL cholesterol ratio 3.71.2 3.61.2 3.61.2 3.81.2
Glucose metabolism status
Normal glucose metabolism 1575 (56.8) 612 (67.4) 522 (55.9) 432 (47.1)
Prediabetes 416 (15.0) 112 (12.2) 151 (16.2) 153 (16.7)
Type 2 diabetes 782 (28.2) 188 (20.4) 261 (27.9) 333 (36.3)
Use of lipid-modifying medication 1004 (36.2) 278 (30.2) 330 (35.3) 396 (43.1)
Use of antihypertensive medication 1101 (39.7) 284 (30.8) 371 (39.7) 446 (48.6)
Beta blockers 488 (17.6) 130 (14.1) 162 (17.3) 196 (21.4)
Diuretics 448 (16.2) 104 (11.3) 170 (18.2) 174 (19.0)
Calcium channel blockers 244 (8.8) 72 (7.8) 88 (9.4) 84 (9.2)
Angiotensin-converting enzyme inhibitors 342 (12.3) 77 (8.4) 107 (11.5) 158 (17.2)
Angiotensin II receptor blockers 491 (17.7) 122 (13.2) 174 (18.6) 195 (21.2)
Mean BP
24-h SBP (mmHg 120.111.7 115.99.7 120.011.7 124.312.7
24-h DBP (mmHg) 74.47.1 72.76.3 74.47.2 76.17.4
BPV measures
Within-visit systolic BPV (mmHg) 4.692.91 2.771.46 4.431.99 6.883.30
Within-visit diastolic BPV (mmHg) 2.511.68 2.141.31 2.411.46 2.992.07
24-h systolic BPV (mmHg) 10.032.50 8.161.32 9.881.58 12.072.61
24-h diastolic BPV (mmHg) 7.011.86 6.241.35 6.881.65 7.912.10
7-day systolic BPV (mmHg) 9.253.83 6.911.70 8.842.28 12.154.80
7-day diastolic BPV (mmHg) 5.762.93 4.761.65 5.371.80 7.244.14
Measures of MVD
Cerebral small vessel disease composite score, per point 0.660.84 0.520.77 0.70 .086 0.780.87
Flicker light-induced retinal arteriolar and venular
dilation response composite score, SD
0.011.00 0.051.01 0.040.99 0.050.99
Urinary albumin excretion (mg/24 h) 6.8 [4.1–11.8] 5.8 [3.7–9.9] 6.9 [4.0–12.5] 7.6 [4.7–13.6]
Heat-induced skin hyperemia (%) 1124781 1164841 1130745 1083756
Plasma biomarkers of MVD composite score (SD) 0.010.99 0.120.99 0.040.98 0.120.99
Data are presented as mean standard deviation, median [interquartile range] or n (%). Data were available for: within-visit blood pressure variability, n¼2768; 24-h blood pressure
variability, n¼2773 7-day blood pressure variability, n¼1950; cerebral small vessel disease composite score, n¼1837; flicker light-induced arteriolar and venular dilation, n¼1844;
urinary albumin excretion, n¼2748; skin hyperemia, n¼1320, and plasma biomarkers of microvascular dysfunction, n¼2685. BP, blood pressure; BPV, blood pressure variability; HDL,
high-density lipoprotein; MVD, microvascular dysfunction.
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flicker light-induced retinal arteriolar and venular dilation
response, and plasma biomarkers of MVD. Estimations of
these associations may have been more inaccurate (i.e.
larger confidence intervals), because of higher measure-
ment errors in these MVD measures as compared with UAE:
CSVD features, flicker light-induced retinal arteriolar and
venular dilation response, and plasma biomarkers of MVD
were measured only once, whereas UAE was based on two
24-h urine samples. In addition, estimations of the associ-
ations may have been more inaccurate with CSVD features
and retinal arteriolar and venular dilation response because
of relatively less available data (n¼ 1837 and n¼ 1844,
respectively) as compared with UAE (n¼ 2748).
As expected, we did not find an association between
BPV and heat-induced skin hyperemia. The skin has rela-
tively high microvascular impedance [4], and, therefore,
most of the increased pulsatile energy related to greater
BPV may be dissipated by arteries and large arterioles
proximal to the skin capillaries [60].
Strengths of this study include the large study population
of community-dwelling participants, assessment of micro-
vascular function in various vascular beds and the extensive
adjustment for potential confounders.
Our study has several limitations. First, our cross-sec-
tional data preclude reaching causal conclusions about the
study findings. Indeed, the reverse association may hold
TABLE 2. Associations between SBP and DBP variability composite scores and microvascular dysfunction measures
SBP variability composite
score, per SD
DBP variability composite
score, per SD
Microvascular dysfunction measure Model b (95% CI) b (95% CI)
Cerebral small vessel disease composite score, per point 1 1.07 (1.01–1.13) 1.07 (1.00–1.13)
2 1.06 (1.00–1.12) 1.06 (0.99–1.12)
3 1.03 (0.97–1.10) 1.03 (0.97–1.10)
4 1.02 (0.96–1.09) 1.03 (0.97–1.10)
Flicker light-induced retinal arteriolar and
venular dilation composite score, per SD
1 0.033 (0.014 to 0.081) 0.021 (0.030 to 0.071)
2 0.021 (0.027 to 0.069) 0.014 (0.036 to 0.064)
3 0.030 (0.020 to 0.081) 0.027 (0.023 to 0.078)
4 0.031 (0.019 to 0.082) 0.025 (0.025 to 0.076)
Urinary albumin excretion, higher ratio 1 1.14 (1.10–1.18) 1.13 (1.09–1.17)
2 1.11 (1.07–1.15) 1.11 (1.09–1.15)
3 1.05 (1.01–1.09) 1.09 (1.09–1.13)
4 1.04 (1.00–1.08) 1.07 (1.03–1.11)
Heat-induced skin hyperemia, per SD 1 0.027 (0.029 to 0.083) 0.007 (0.050 to 0.064)
2 0.006 (0.051 to 0.063) 0.009 (0.066 to 0.048)
3 0.001 (0.060 to 0.058) 0.006 (0.064 to 0.052)
4 0.005 (0.054 to 0.065) 0.003 (0.061 to 0.055)
Plasma biomarkers of microvascular
dysfunction composite score, per SD
1 0.089 (0.052–0.126) 0.082 (0.043 0.120)
2 0.052 (0.015–0.088) 0.054 (0.017–0.092)
3 0.057 (0.019–0.095) 0.056 (0.018–0.093)
4 0.035 (0.001 to 0.072) 0.023 (0.013 to 0.060)
Results [b (95% confidence interval)] are expressed as rate ratio for higher cerebral small vessel disease composite score, SD lower flicker light-induced retinal arteriolar and venular
dilation composite score, higher ratio urinary albumin excretion, SD lower heat-induced skin hyperemia, and SD higher plasma biomarkers of microvascular dysfunction composite score
(all indicating worse microvascular function), and per SD higher SBP or DBP variability composite score. Model 1: adjusted for age, sex; model 2: model 1 þ glucose metabolism status;
model 3: model 2 þ mean 24-h SBP or DBP (wherever appropriate); model 4: model 3 þ education level, BMI, smoking status, alcohol consumption, total/high density lipoprotein
cholesterol ratio, lipid-modifying medication, and the individual classes of antihypertensive medication (i.e. beta blockers, diuretics, calcium channel blockers, angiotensin-converting
enzyme inhibitors and angiotensin II receptor blockers). Bold denotes P value less than 0.05. CI, confidence interval; SD, standard deviation.
S y s to l ic  B P V  c o m p o s it e  s c o r e 1 .1 9  (1 .0 2  – 1 .3 8 )
1 .1 9  (1 .0 2  – 1 .3 7 )D ia s t o l ic  B P V  c o m p o s it e  s c o r e
h ig h e r o d d s U A E  > = 3 0  m g /2 4 h
O R  (9 5 % C I )
lo w e r o d d s  U A E  > = 3 0  m g /24h
0 .8 1 .21 .0 1 .40 .9
FIGURE 2 Associations of SBP and DBP variability composite scores with urinary albumin excretion dichotomized as at least 30 mg/24 h vs. less than 30 mg/24 h. Point
estimates represent the odds ratio of urinary albumin excretion per standard deviation higher systolic or diastolic BPV composite score. Results are adjusted for age, sex,
glucose metabolism status, mean 24-h SBP or DBP (wherever appropriate), education level, BMI, smoking status, alcohol consumption, total/high density lipoprotein
cholesterol ratio, lipid-modifying medication, and the individual classes of antihypertensive medication. BPV, blood pressure variability; CI, confidence interval; OR, odds
ratio; UAE, urinary albumin excretion.
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true as well, that is, higher UAE (as a reflection of worse
kidney function) may lead to greater BPV [61]. However,
when we additionally adjusted our analyses for estimated
glomerular filtration rate, results were similar. Second, as
we performed a large number of tests in interaction anal-
yses, we cannot exclude that some findings may reflect the
play of chance because of multiple testing. Future valida-
tion of these inconsistent (hypothesis-generating) observa-
tions is warranted. Third, the use of a BPV composite score
assumes that all BPV measures share similar underlying
mechanisms that lead to MVD, which may not necessarily
be true. However, when we repeated the analyses with the
individual BPV measures, results were qualitatively similar.
This may suggest that BPV measures share similar underly-
ing mechanisms that lead to MVD (even though individual
measures of BPV are determined by different haemody-
namic mechanisms) [62]. Fourth, the association between
greater BPV and UAE may be the result of residual con-
founding because of low-grade inflammation [63,64], arte-
rial stiffening [4,65], activation of the renin–angiotensin
system [66,67], unhealthy dietary habits [68,69], physical
inactivity [70,71] and lower socioeconomic status [72,73].
However, when we adjusted for low-grade inflammation,
carotid–femoral pulse wave velocity, the diet score, mod-
erate-to-vigorous physical activity and factors related to
socioeconomic status (i.e. education, income level and
occupation status), results did not materially change. In
this study, no data were available on activation of the renin–
angiotensin system; however, and this issue requires further
study. Fifth, we may have underestimated the association
between greater BPV and MVD as individuals excluded for
the present analysis because of missing data had greater
BPV and a higher prevalence of prior cardiovascular dis-
ease than those included in the analysis. Finally, the study
population consisted mainly of middle-aged individuals
who were relatively well educated and whose cardiovas-
cular risk factors were relatively well controlled. This may
have led to an underestimation of the association between
BPV and MVD.
Perspectives
In conclusion, this large, relatively healthy population-
based study showed that greater very short-term to mid-
term systolic and diastolic BPV was associated with higher
UAE, but not with other measures of MVD tested, that is,
CSVD features, flicker light-induced retinal arteriolar and
venular dilation response, heat-induced skin hyperemia
and plasma biomarkers of MVD. This may suggest that
the microvasculature of the kidneys is most vulnerable to
the detrimental effects of greater BPV. Future longitudinal
studies should confirm these associations and, if verified,
intervention studies should assess whether lowering BPV
may prevent albuminuria.
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